Improving the Lives of Women With Ovarian Cancer.
Journal
Clinical obstetrics and gynecology
ISSN: 1532-5520
Titre abrégé: Clin Obstet Gynecol
Pays: United States
ID NLM: 0070014
Informations de publication
Date de publication:
15 Jan 2024
15 Jan 2024
Historique:
medline:
17
1
2024
pubmed:
17
1
2024
entrez:
17
1
2024
Statut:
aheadofprint
Résumé
Being a gynecologic oncologist is a privilege. Women with cancer address their challenges with grit and resilience. Their most basic questions motivated my career-long search for scientific answers hidden in genetics, novel therapeutics, and cancer prevention. But medicine is a team sport. Working alongside gifted colleagues and mentoring trainees to assume starring roles on the team has sustained and enriched my career. Advocating for patients and the specialty of gynecologic oncology provided another means to advance research and cancer awareness to improve patient outcomes. The author believe the most exciting times are yet to come.
Identifiants
pubmed: 38230704
doi: 10.1097/GRF.0000000000000851
pii: 00003081-990000000-00137
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Karlan BY, Baldwin RL, Lopez-Luevanos E, et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol. 1999;180:917–928.
Karlan BY, Platt LD. Ovarian cancer screening: the role of ultrasound in early detection. Cancer. 1995;76(suppl):2011–2015.
Cancer Genome Atlas Research Network (Karlan BY) Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134–147.
Goode EL, Block MS, Kalli KR, et alOvarian Tumor Tissue Analysis (OTTA) Consortium. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 2017;3:3–12.
Phelan CM, Kuchenbaecker KB, Tyrer JP, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49:680–691.
Walsh CS, Ogawa S, Karahashi H, et al. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol. 2008;26:2952–2958.
Cheon DJ, Tong Y, Sim MS, et al. A collagen-remodeling gene signature regulated by TGF signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014;20:711–723.
Karlan BY, Dering J, Walsh C, et al. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol;. 2014;132:334–342.
Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 2000;66:1259–1272.
Liede A, Karlan BY, Baldwin RL, et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol. 2002;20:1570–1577.
Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187–2195.
Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307:382–390.
Baldwin RL, Nemeth E, Tran H, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000;60:5329–5333.
Chiang JW, Karlan BY, Cass I, et al. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol. 2006;101:403–410.
Gull N, Jones MR, Peng PC, et al. DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers. J Exp Clin Cancer Res. 2022;41:232–250.
Walsh CS, Ogawa S, Scoles DR, et al. Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas. Clin Cancer Res. 2008;14:7645–7651.
Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28:3555–3561.
Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116–1120.
Swisher EM, Sakai W, Karlan BY, et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008;68:2581–2586.
Cass I, Walts AE, Barbuto D, et al. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers. Gynecol Oncol. 2014;134:492–497.
Zakhour M, Danovitch Y, Lester J, et al. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol Oncol. 2016;143:231–235.
Kotsopoulos J, Karlan BY, Gronwald J, et al. Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers. Int J Gynecol Cancer. 2020;6:825–830.
Daly M, Dresher CW, Yates MS, et al. Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res. 2015;8:342–348.
Yucer N, Ahdoot R, Workman MJ, et al. Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis. Cell Rep. 2021;37:110146.
Yucer N, Holzapfel M, Jenkins Vogel T, et al. Directed differentiation of human induced pluripotent stem cells into fallopian tube epithelium. Sci Rep. 2017;7:10741.
Morgan KM, Hamilton JG, Symecko H, et al. Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web- enabled medical model: an observational cohort study. Genet Med. 2022;24:564–575.
Karlan BY. Testimony before the subcommittee on criminal justice, drug policy and human resources: Committee on Government Reform United States House of Representatives. Gynecol Oncol. 2005;99:257–260.
Karlan BY. Evolution through intelligent design. Gynecol Oncol. 2006;102:1–4.
Karlan BY. Dawn of a new era for Gynecologic Oncology. Gynecol Oncol. 2008;108:2.
Karlan BY. It’s time to pass the baton. Gynecol Oncol. 2021;163:445.